Table 1. Retrospective studies including... | American Society of Hematology

Table 1.

Retrospective studies including patients treated with DOACs included in the study by Giustozzi et al

First author, year	Quality∗	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	Total DOAC	LMWH	Warfarin
Carney et al, 2019⁶	Poor	20	5	0	16	41	131	—
Primary	—	15	0	0	5	20	47	—
Metastatic	—	5	5	0	11	21	84	—
De Melo Jr et al, 2020¹⁰	Poor	2	0	0	19	21	4	29
Leader et al, 2020⁷	Good	—	—	—	—	—	—	—
Metastatic	—	11	5	8	17	41	55	—
Lee et al, 2021⁸	Good	13	1	5	38	57	56	—
Dubinski et al, 2022⁹	Good	0	0	8	6	14	32	—
Total		46	11	21	96	174	278	29

First author, year	Quality∗	Apixaban	Dabigatran	Edoxaban	Rivaroxaban	Total DOAC	LMWH	Warfarin
Carney et al, 2019⁶	Poor	20	5	0	16	41	131	—
Primary	—	15	0	0	5	20	47	—
Metastatic	—	5	5	0	11	21	84	—
De Melo Jr et al, 2020¹⁰	Poor	2	0	0	19	21	4	29
Leader et al, 2020⁷	Good	—	—	—	—	—	—	—
Metastatic	—	11	5	8	17	41	55	—
Lee et al, 2021⁸	Good	13	1	5	38	57	56	—
Dubinski et al, 2022⁹	Good	0	0	8	6	14	32	—
Total		46	11	21	96	174	278	29

As assessed by Giustozzi et al.